Linda Stein Gold, MD, introduces the panel and outlines the discussion’s focus on emerging therapies and evolving clinical approaches in psoriasis and PsA management.
Back
Redefining Psoriasis Care: Expert Perspectives of Emerging Data on Novel Treatment Modalities
In this HCPLive Peer Exchange, Linda Stein Gold, MD, moderates a dynamic discussion with Jennifer Soung, MD, and David Cotter, MD, exploring how recent advances in psoriasis and psoriatic arthritis research are transforming patient management. The panel examines persistent treatment gaps, evolving patient preferences favoring oral options, and new guideline updates redefining “topical failure.” They highlight pivotal data from EADV 2025, including the ICONIC-ADVANCE and ICONIC-LEAD trials of icotrokinra (ICO)—a first-in-class oral IL-23 receptor antagonist—and the APEX study of guselkumab in psoriatic arthritis, which demonstrated significant inhibition of radiographic progression. The discussion emphasizes patient-centered, mechanism-driven approaches to psoriasis and PsA care, underscoring how emerging oral and biologic therapies are reshaping treatment paradigms
Redefining Psoriasis Care: Expert Perspectives of Emerging Data on Novel Treatment Modalities
Episodes
All
All
Dr. Stein Gold introduces the panel and outlines the discussion’s focus on emerging therapies and evolving clinical approaches in psoriasis and PsA management.
Discussion on how patient goals, treatment experiences, and preference for oral agents shape individualized therapy plans.
The experts analyze new patient and clinician survey data, revealing gaps between treatment satisfaction and practice realities.
Review of the updated IPC framework defining topical failure, reducing “topical churn,” and guiding earlier systemic escalation.
The panel explores patient attitudes toward oral vs injectable treatments and practical limitations of current oral agents.
Jennifer Soung, MD, outlines ICO’s mechanism as an IL-23 receptor antagonist and its significance in oral systemic therapy.
Overview of the ADVANCE trials showing ICO’s superior efficacy to deucravacitinib and consistent safety across 24 weeks.
Discussion of nasopharyngitis and URTI as the most common AEs and how the safety profile compares to other oral agents.
Review of new week 52 results showing durable responses and strong efficacy in both adults and adolescents.
Examination of unique challenges and the importance of early, effective therapy in younger patients.
Debate on whether early IL-23–targeted therapy like ICO could delay or prevent PsA onset.
The panel discusses the prevalence and risk factors for psoriasis progression to psoriatic arthritis.
Summary of the phase 3b APEX study showing guselkumab’s efficacy and inhibition of structural joint damage.
Comparison of APEX findings to prior IL-23 trials such as KEEPSAKE-1 and their implications for clinical practice.
Highlights from Fall Clinical 2025, including emerging IL-23 and real-world data shaping the next phase of psoriasis research.
Final reflections from physicians Stein Gold, Soung, and Cotter, emphasizing multidisciplinary, patient-focused advances in psoriasis and PsA care.
Advertisement
Advertisement
Trending on HCPLive
1
Kidney Compass: VISIONARY 2-Year eGFR Data in IgA Nephropathy
2
Bimekizumab Data Support Case for Earlier Intervention in HS
3
ACC Statement Examines Frailty, Cognitive Impairment, in Cardiovascular Disease
4
BE HEARD EXT: Bimekizumab Shows Greater Benefit With Earlier Use in HS
5